Serum levels of secreted group IIA phospholipase A2 in benign prostatic hyperplasia and prostate cancer: A biomarker for inflammation or neoplasia?

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

Abstract

Secreted group IIA phospholipase A 2 (sPLA 2-IIA) is markedly up-regulated in human prostate cancer (PCa) specimens and in some PCa-derived cell lines, indicating an important role of this enzyme in tumourigenesis. In this study, we measured levels of sPLA 2-IIA, C-reactive protein (CRP), and prostate-specific antigen (PSA) in serum samples obtained from patients with benign prostatic hyperplasia (BPH) and with PCa of different stages. We found that serum levels of sPLA 2- IIA and CRP in BPH and PCa patients were significantly elevated compared to those of healthy individuals, but the concentrations of these inflammatory biomarkers did not differ between patients with BPH or PCa. Furthermore, serum levels of sPLA 2-IIA correlated with concentrations of CRP, but not with PSA, Gleason grade or tumour stage. In conclusion, these findings suggest that cancerrelated changes are not exclusive factors contributing to elevated serum sPLA 2-IIA levels and emphasize the utility of sPLA 2-IIA as a circulating marker of inflammation in patients with BPH and PCa.

Details

Original languageEnglish
Pages (from-to)1113-1118
Number of pages6
JournalInflammation
Volume35
Issue number3
Publication statusPublished - Jun 2012
Peer-reviewedYes

External IDs

PubMed 22189868

Keywords

Sustainable Development Goals

ASJC Scopus subject areas

Keywords

  • Benign prostatic hyperplasia, C-reactive protein, Inflammation, Prostate cancer, Secreted phospholipase A